Main Products/ Services/ Pipelines & Platforms
Antibody drugs lead to serious side effects because they cannot distinguish disease tissue from normal tissue. Universal Antibody Lock allows antibody drugs to take effect only in diseased areas, solving systemic toxicity, and making antibody treatment safe and effective. Compared to competitors, our Lock-antibody ▪ Features: ▪ Higher masking ability and removal ability ▪ Low immunogenicity ▪ Prevention of anti-drug antibody binding ▪ Prolonged serum half-life ▪ Lead Product: PSM101, the lead candidate for head and neck cancer and colorectal cancer treatment, will complete stable cell clone generation in 2023 and the non-human primate side effect test in 2024-Q1. ▪ Partnering: Through (1) co-development of Lock-antibodies and (2) customized Antibody Lock design service, PrecisemAb licenses out Lock-antibodies to global pharma for conducting further clinical trials.
Business Interests
▪ Cooperation Partners of Lead Product-PSM101 ▪ Strategic Partners of ADC. ▪ Customized Antibody Lock design service ▪ Out-licensing of Lock-antibodies
Contact Info
LiChen Yen
BD Manager
+886-7311-1577
lichen.yen@ precisemab.com